You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

Drugs

The drug library provides access to information on over 100 cancer drugs available for use in Canada.

Displaying Drugs List

27 Items
Other Name(s): Giotrif® (Boehringer Ingelheim)
Funding:
Exceptional Access Program
  • AFAtinib - For first-line monotherapy treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC), according to specific criteria
Aug 2017
Other Name(s): Alecensaro™ (Hoffman-La Roche Limited)
Dec 2016
Other Name(s): Avastin® (Hoffmann-LaRoche)
Funding:
New Drug Funding Program
  • Bevacizumab - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
  • Bevacizumab in combination with paclitaxel and carboplatin - Front-line Treatment Ovarian Fallopian Tube and Primary Peritoneal Cancer
  • Bevacizumab - First Line - Metastatic Colorectal Small Bowel or Appendiceal Cancer
  • Bevacizumab for Platinum-Resistant Recurrent Ovarian Fallopian Tube or Primary Peritoneal Cancer
Nov 2017
Other Name(s): Paraplatin AQ® (multiple brands available)
Aug 2016
Other Name(s): Zykadia (TM) (Novartis )
Apr 2016
Other Name(s): Platinol AQ® (multiple brands available)
Aug 2016
Other Name(s): Xalkori® (Pfizer)
Funding:
Exceptional Access Program
  • crizotinib - ALK-positive advanced NSCLC, according to specific criteria
Sep 2017
Other Name(s): Procytox® (Baxter)
Funding:
ODB - General Benefit
  • cyclophosphamide - oral tablets
Nov 2017
Other Name(s): Tafinlar® (Novartis)
Funding:
Exceptional Access Program
  • daBRAfenib - As monotherapy for the first-line and second-line treatment of patients with BRAF V600 mutation-positive unresectable melanoma or metastatic disease, according to specific criteria
  • daBRAfenib - In combination with trametinib for the treatment of BRAF V600 mutation-positive, unresectable or metastatic melanoma and other indications, according to specific clinical criteria
Aug 2017
Other Name(s): Taxotere® (multiple brands available)
Funding:
New Drug Funding Program
  • Docetaxel - Metastatic Castration-Resistant Prostate Cancer
  • Docetaxel - Non-Small Cell Lung Cancer (NSCLC)
  • Docetaxel - Non-Small Cell Lung Cancer (Second or Subsequent Line)
  • Docetaxel - Neoadjuvant treatment for Non-Metastatic Breast Cancer
  • Docetaxel - Metastatic Breast Cancer
  • Docetaxel - Hormone Sensitive Prostate Cancer
  • Trastuzumab with First Line Docetaxel - Metastatic Breast Cancer
  • Docetaxel - CYCLDOCE for Early Operable Breast Cancer
  • Docetaxel - FEC-D or AC-DOCE for Adjuvant Treatment for Breast Cancer
Nov 2017
Other Name(s): Adriamycin PFS® (multiple brands available)
Nov 2017
Other Name(s): Tarceva® (Hoffmann-LaRoche)
Funding:
Exceptional Access Program
  • erlotinib - Incurable progressive NSCLC, with specific criteria
May 2017